Table 1.

Clinical data of patients who had primary MN and were enrolled in the study

ParameterPatient
123456789101112131415161718192021222324
GenderMFMMMFMMMMMFMMMFMFMFMMFF
Age at diagnosis475163707372385773575952606735747558646828404347
Histologic stageI to III to IIIII to IIIII to III to IIIIII to IIIIIIIIII to IIIIIIIII to IIIIIIIIIIIIII
Serum creatinine (mg/dl)
    at diagnosis0.91.72.86.02.30.50.90.71.40.90.90.81.11.00.91.72.00.70.61.10.81.40.60.7
    after 1 year1.13.82.21.42.0NA0.91.01.50.91.10.70.9NA0.91.61.50.90.61.00.71.10.80.7
Serum albumin (g/dl)
    at diagnosis1.92.73.21.91.81.23.92.42.03.12.42.71.61.82.31.91.72.41.62.23.11.5NA2.3
    after 1 year4.01.53.42.82.1NA3.93.72.73.82.44.02.6NA3.02.94.03.02.32.03.82.2NA4.0
Proteinuria (g/d)
    at diagnosis6.85.012.010.06.03.53.016.011.06.05.01.728.08.06.46.09.02.83.74.711.518.00.55.4
    after 1 year0.210.01.53.52.0NA0.20.110.80.07.00.42.2NA0.60.62.25.32.34.44.310.00.60.2
Anti-HCVYYY
Immunosuppressant therapyYYYYYYYYYYYYYYYYYYY
ACEI/ARBYYYYYYYYYYYYYYYYYYYYY
Proteomics + dot blotYYYYYYYYYYYYYYYYYY
  • Patient 6 died 5 months after diagnosis because of hepatic failure. Patient 14 was lost to follow-up. Immunosuppressant therapy was conducted as described in the Concise Methods section. Patients 1 through 17 underwent a complete screening with qualitative Western blot and quantitative dot blot. ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; HCV, hepatitis C virus; NA, not available; Y, yes.